Ashley Bailey-Classen, DO
Pain Medicine · Fort Worth, TXNPI 1639583925
Payments from drug & device makers
Across 705 payments — averaging $345.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spinal Simplicity, LLC$90K
- Globus Medical$58K
- Nevro Corp.$37K
- Medtronic$30K
- Aurora Spine, Inc.$17K
- Saluda Medical Americas, Inc.$2K
- plus $10K from 26 others
Across 1 payment — averaging $345.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$345
What the payments were for
- Consulting fees$67,46628%
- Speaking & faculty fees$80,13033%
- Travel & lodging$30,32412%
- Food & beverage$23,38410%
- Education$42,21017%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Spinal Simplicity, LLC | 123 | $89,984 |
| Globus Medical | 68 | $58,089 |
| Nevro Corp. | 120 | $36,892 |
| Medtronic(2 entities) | 215 | $29,717 |
| Aurora Spine, Inc. | 6 | $16,966 |
| Saluda Medical Americas, Inc. | 8 | $2,207 |
| Biotronik NRO, Inc. | 10 | $1,731 |
| Boston Scientific | 30 | $1,341 |
| Painteq LLC | 13 | $1,083 |
| Abbott | 17 | $940 |
| Surgentec | 3 | $856 |
| Vertiflex, Inc. | 9 | $504 |
| Nalu Medical, Inc. | 20 | $498 |
| Vertos Medical, Inc. | 4 | $384 |
| Amgen | 10 | $333 |
| SPR Therapeutics, Inc | 4 | $300 |
| Si-bone, Inc. | 5 | $282 |
| Stimwave Technologies Incorporated | 2 | $237 |
| Relievant Medsystems, Inc. | 2 | $175 |
| Lundbeck LLC | 5 | $166 |
| Vertex | 6 | $151 |
| Tersera Therapeutics LLC | 5 | $132 |
| Pfizer | 8 | $130 |
| Foundation Fusion Solutions, LLC | 1 | $107 |
| Stryker | 2 | $102 |
| Genesys Orthopedics Systems, L.L.C. | 2 | $56 |
| MML US, Inc. | 1 | $50 |
| Forte Bio-pharma LLC | 2 | $47 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Biogen | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HA MINUTEMAN G3-R$88,018
- Senza$63,865
- SILO TFX MIS SACROILIAC JOINT FIXATION SYSTEM$16,966
- INTELLIS ADAPTIVESTIM$9,506
- Omnia$8,769
- Vyrsa V1$8,334
- VANTA ADAPTIVESTIM$6,920
- Senza Spinal Cord Stimulation System$2,731
- SYNCHROMEDII$2,065
- Evoke SCS$2,050
- RESTORE$1,980
- INTELLIS$1,727
- Prospera$1,523
- SYNCHROMED$1,361
- 3D GraftRasp System$832
- PAINTEQ$803
- Intracept$657
- Vanta$647
- Superion ISS$419
- mild Device Kit$259
How this compares
$243,529 in reported general payments places this provider in the 95th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $4,135 |
| Celecoxib | 78 | $2,519 |
| Gabapentin | 152 | $1,968 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $1,577 |
| Methocarbamol | 97 | $1,477 |
| Naloxone Hcl | 20 | $1,270 |
| Pregabalin | 48 | $962 |
| Duloxetine Hcl | 38 | $818 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 21 | $580 |
| Baclofen | 27 | $543 |
| Amitriptyline Hcl | 44 | $496 |
| Cefadroxil | 57 | $370 |
| Tizanidine Hcl | 12 | $318 |
| Cyclobenzaprine Hcl | 26 | $301 |
| Tramadol Hcl | 27 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $18 | $4,13527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Fort Worth
- Christopher PrattFort Worth$34K
- Israel PenaFort Worth$24K
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Muhammad ZulqarnainDallas$556K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
- David LeimanHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.